A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
Recruiting
1,100 enrolled
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
Phase 2 Recruiting
285 enrolled
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
949 enrolled
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
Phase 1 Recruiting
100 enrolled
The Vanguard Study: Testing a New Way to Screen for Cancer
Phase NA Recruiting
24,000 enrolled
Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
Recruiting
1,000 enrolled
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Phase 2 Recruiting
200 enrolled
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
Phase 1 Recruiting
40 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
RAINFOL-01
Phase 1/2 Recruiting
764 enrolled
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Phase 1 Recruiting
113 enrolled
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
386 enrolled
DP-04
Recruiting
100 enrolled
RAD301
Phase 1 Recruiting
9 enrolled
ASAP
Recruiting
25,000 enrolled
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
Phase 2 Recruiting
320 enrolled
BetaBart
Phase 1/2 Recruiting
61 enrolled
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Phase 1 Recruiting
226 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Phase 1 Recruiting
280 enrolled
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
Phase 1 Recruiting
40 enrolled
CHANCES
Phase 1 Recruiting
27 enrolled
ADVICE
Phase 1/2 Recruiting
80 enrolled
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Phase 1/2 Recruiting
182 enrolled
PRO-ACTIVE
Recruiting
850 enrolled
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Phase 1/2 Recruiting
300 enrolled
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Phase 1 Recruiting
258 enrolled
NAPISTAR1-01
Phase 1/2 Recruiting
250 enrolled
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
Phase 2 Recruiting
24 enrolled
FONTANA
Phase 1/2 Recruiting
506 enrolled
IDOV-Immune for Advanced Solid Tumors
Phase 1 Recruiting
78 enrolled
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
Recruiting
25 enrolled
EVEREST-2
Phase 1/2 Recruiting
474 enrolled
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Phase 1/2 Recruiting
159 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
SELECT-CAR-NK
Phase 1/2 Recruiting
85 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1 Recruiting
100 enrolled
IT-TCP POS
Phase NA Recruiting
300 enrolled
BASECAMP-1
Recruiting
200 enrolled
GUARDIAN-101
Phase 1 Recruiting
90 enrolled
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Phase 1 Recruiting
150 enrolled
The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia.
Phase NA Recruiting
9 enrolled
SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
Phase 1 Recruiting
42 enrolled
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Phase 1/2 Recruiting
534 enrolled
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Phase 2 Recruiting
492 enrolled
A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
250 enrolled